Use of Anti-Retroviral Therapy in Tuberculosis Patients on Second-Line Anti-TB Regimens: A Systematic Review

• Matthew Arentz ,

  * E-mail: marentz@u.washington.edu

  Affiliation The University of Washington, Seattle, Washington, United States of America

  ⨯
• Patricia Pavlinac,

  Affiliation The University of Washington, Seattle, Washington, United States of America

  ⨯
• Michael E. Kimerling,

  Affiliation The Bill and Melinda Gates Foundation, Seattle, Washington, United States of America

  ⨯
• David J. Horne,

  Affiliation The University of Washington, Seattle, Washington, United States of America

  ⨯
• Dennis Falzon,

  Affiliation World Health Organization, Geneva, Switzerland

  ⨯
• Holger J. Schünemann,

  Affiliation McMaster University, Hamilton, Canada

  ⨯
• Sarah Royce,

  Affiliation University of California San Francisco, San Francisco, California, United States of America

  ⨯
• Keertan Dheda,

  Affiliations Institute of Infectious Diseases and Molecular Medicine, The University of Cape Town, Cape Town, South Africa, The Division of Pulmonology, The University of Cape Town, Cape Town, South Africa, UCT Lung Institute, The University of Cape Town, Cape Town, South Africa

  ⨯
• Judd L. Walson, for the ART/DR-TB study group

  Membership of the ART study group is listed in the Acknowledgments.

  Affiliation The University of Washington, Seattle, Washington, United States of America

  ⨯